

ASX ANNOUNCEMENT

23 January 2026

## \$1.2m At-The-Market Raise

**Melbourne, Australia; 23 January 2026:** [Cynata Therapeutics Limited](#) (ASX: “CYP” or “Cynata”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has utilised its At-the-Market Subscription Agreement (“ATM”) with Acuity Capital (see [announcement released on 22 August 2025](#)) to raise \$1,204,000 (net of costs) through the set-off of 4,300,000 fully paid ordinary Cynata shares previously issued to Acuity Capital under the ATM (“Set-off Shares”).

The Set-off Shares have a deemed issue price of \$0.28 per share, which represents a discount of 11.1% to the last traded price of \$0.315 on 23 January 2026.

The funds raised will be put towards working capital.

**-ENDS-**

**Authorised for release by Dr Kilian Kelly, CEO & Managing Director**

**CONTACTS:** Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, [kilian.kelly@cynata.com](mailto:kilian.kelly@cynata.com)  
Lauren Nowak, Media Contact, +61 (0)400 434 299, [investors@cynata.com](mailto:investors@cynata.com)

### **About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges and limitations of conventional MSC production by using induced pluripotent stem cells (iPSCs) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the necessity to obtain tissue from multiple donors on an ongoing basis, and without the complexity and product inconsistency resulting from conventional methods.

Cynata has demonstrated positive safety and efficacy data for its Cymerus™ product candidates CYP-001 and CYP-006TK in Phase 1 clinical trials in steroid-resistant acute graft versus host disease (GvHD) and diabetic foot ulcers (DFU), respectively. Further clinical trials are now ongoing: a Phase 2 trial of CYP-001 in GvHD under a cleared US FDA IND; a Phase 1/2 trial of CYP-001 in patients undergoing kidney transplantation; and a Phase 3 trial of CYP-004 in osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus™ technology in preclinical models of numerous other diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

**Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, [Automatic Group](#).**